Angiocrine signals regulate quiescence and therapy resistance in bone metastasis.


Journal

JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073

Informations de publication

Date de publication:
11 07 2019
Historique:
received: 18 10 2018
accepted: 24 05 2019
entrez: 12 7 2019
pubmed: 12 7 2019
medline: 22 7 2020
Statut: epublish

Résumé

Bone provides supportive microenvironments for hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) and is a frequent site of metastasis. While incidences of bone metastases increase with age, the properties of the bone marrow microenvironment that regulate dormancy and reactivation of disseminated tumor cells (DTCs) remain poorly understood. Here, we elucidate the age-associated changes in the bone secretome that trigger proliferation of HSCs, MSCs, and DTCs in the aging bone marrow microenvironment. Remarkably, a bone-specific mechanism involving expansion of pericytes and induction of quiescence-promoting secretome rendered this proliferative microenvironment resistant to radiation and chemotherapy. This bone-specific expansion of pericytes was triggered by an increase in PDGF signaling via remodeling of specialized type H blood vessels in response to therapy. The decline in bone marrow pericytes upon aging provides an explanation for loss of quiescence and expansion of cancer cells in the aged bone marrow microenvironment. Manipulation of blood flow - specifically, reduced blood flow - inhibited pericyte expansion, regulated endothelial PDGF-B expression, and rendered bone metastatic cancer cells susceptible to radiation and chemotherapy. Thus, our study provides a framework to recognize bone marrow vascular niches in age-associated increases in metastasis and to target angiocrine signals in therapeutic strategies to manage bone metastasis.

Identifiants

pubmed: 31292293
pii: 125679
doi: 10.1172/jci.insight.125679
pmc: PMC6629249
doi:
pii:

Substances chimiques

Adrenergic alpha-1 Receptor Antagonists 0
Antineoplastic Agents 0
Prazosin XM03YJ541D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MC_UP_1605/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P02209X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202300/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Cancer Research UK
Pays : United Kingdom

Références

Nature. 2000 Sep 14;407(6801):249-57
pubmed: 11001068
Nat Rev Cancer. 2002 Aug;2(8):584-93
pubmed: 12154351
Clin Exp Metastasis. 2003;20(3):275-84
pubmed: 12741685
Genes Dev. 2003 Aug 1;17(15):1835-40
pubmed: 12897053
Ageing Res Rev. 2006 Feb;5(1):91-116
pubmed: 16310414
J Clin Invest. 2006 Mar;116(3):642-51
pubmed: 16470244
Cell Cycle. 2007 Oct 1;6(19):2371-6
pubmed: 17700071
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Clin Cardiol. 1990 Nov;13(11):764-72
pubmed: 1980236
Cancer Res. 2009 Dec 15;69(24):9245-53
pubmed: 19951996
Nat Rev Immunol. 2010 Mar;10(3):193-200
pubmed: 20154734
J Clin Invest. 2010 Jun;120(6):1800-3
pubmed: 20501952
Cancer Res. 2010 Aug 15;70(16):6537-47
pubmed: 20682798
Nat Rev Endocrinol. 2011 Apr;7(4):208-18
pubmed: 21200394
Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20012-7
pubmed: 22123971
Nat Rev Clin Oncol. 2011 Dec 20;9(2):76-8
pubmed: 22182971
Nat Rev Immunol. 2013 May;13(5):376-89
pubmed: 23584423
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Nat Rev Mol Cell Biol. 2013 Jun;14(6):329-40
pubmed: 23698583
Bioinformatics. 2013 Aug 1;29(15):1900-1
pubmed: 23709494
Nat Cell Biol. 2013 Jul;15(7):807-17
pubmed: 23728425
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Nature. 2014 Mar 20;507(7492):323-328
pubmed: 24646994
Nature. 2014 Mar 20;507(7492):376-380
pubmed: 24647000
Cancer Cell. 2014 Mar 17;25(3):350-65
pubmed: 24651014
Nature. 2014 Aug 14;512(7513):198-202
pubmed: 25079315
Nat Rev Cancer. 2014 Sep;14(9):611-22
pubmed: 25118602
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Genome Biol. 2014;15(12):550
pubmed: 25516281
Stem Cells Transl Med. 2015 Feb;4(2):186-94
pubmed: 25548388
Bonekey Rep. 2015 Apr 22;4:668
pubmed: 25908969
Curr Cancer Drug Targets. 2015;15(6):469-80
pubmed: 25968899
Exp Biol Med (Maywood). 2015 Aug;240(8):1099-106
pubmed: 26088863
Nature. 2016 Jan 21;529(7586):316-25
pubmed: 26791722
Nature. 2016 Apr 21;532(7599):380-4
pubmed: 27074508
Nature. 2016 Apr 21;532(7599):323-8
pubmed: 27074509
Bonekey Rep. 2015 Sep 09;4:742
pubmed: 27217954
Annu Rev Cell Dev Biol. 2016 Oct 6;32:649-675
pubmed: 27576121
J Bone Oncol. 2016 Jul 21;5(3):112-116
pubmed: 27761369
Nat Commun. 2016 Dec 06;7:13601
pubmed: 27922003
Nature. 2017 Mar 9;543(7644):205-210
pubmed: 28241143
EMBO J. 2017 Apr 3;36(7):840-853
pubmed: 28254837
Cell Stem Cell. 2017 Jun 1;20(6):771-784.e6
pubmed: 28330582
Nat Commun. 2017 Jul 18;8:16106
pubmed: 28719590
Cancer Sci. 2017 Oct;108(10):1921-1926
pubmed: 28763139
Science. 2017 Aug 25;357(6353):
pubmed: 28775214
Cancer Cell. 2017 Sep 11;32(3):324-341.e6
pubmed: 28870739
Immunity. 2018 Apr 17;48(4):632-648
pubmed: 29669248
Nat Med. 2018 Jun;24(6):782-791
pubmed: 29736022
Trends Pharmacol Sci. 2019 Feb;40(2):128-141
pubmed: 30612715
Nat Cell Biol. 2019 Apr;21(4):430-441
pubmed: 30936475

Auteurs

Amit Singh (A)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

Vimal Veeriah (V)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

Pengjun Xi (P)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

Rossella Labella (R)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

Junyu Chen (J)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Department of Prosthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Sara G Romeo (SG)

Institute of Clinical Sciences, Imperial College London, London, United Kingdom.
MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.

Saravana K Ramasamy (SK)

Institute of Clinical Sciences, Imperial College London, London, United Kingdom.
MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.

Anjali P Kusumbe (AP)

The Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH